Ajanta Pharma Q3 PAT may dip 35.1% YoY to Rs. 95.8 cr: ICICI Direct

ICICI Direct has come out with its third quarter (October-December’ 18) earnings estimates for the Healthcare sector. The brokerage house expects Ajanta Pharma to report net profit at Rs. 95.8 crore down 35.1% year-on-year (down 23.6% quarter-on-quarter).

Net Sales are expected to decrease by 11 percent Y-o-Y (down 3.9 percent Q-o-Q) to Rs. 522.6 crore, according to ICICI Direct.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 32.8 percent Y-o-Y (down 20.1 percent Q-o-Q) to Rs. 132.7 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.